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Abstract
Objective
Presepsin (soluble CD14 subtype) has been shown to be beneficial as a sepsis marker in
adults. Nevertheless, very few data are available in neonates. The aim of the present study
was to determine reference ranges of presepsin in term and preterm neonates.
Methods
Healthy term neonates and preterm neonates without clinical signs of infection admitted to
the Neonatal Unit were consecutively enrolled. Presepsin concentrations in whole blood
were measured using a point-of-care assay system located in the Unit. Demographic data,
antenatal and perinatal variables commonly affecting C-reactive protein and procalcitonin
values were considered.
Results
Of the 684 neonates enrolled in the study, 484 (70.8%) were born at term and 200 (29.2%) were
preterm (24–36 weeks’ gestation). In term infants, presepsin median value was 603.5 pg/mL
(interquartile range: 466.5–791 pg/mL; 5th and 95th centiles: 315 and 1178 pg/mL respectively).
In preterm infants, presepsin median value was slightly higher, equal to 620 pg/mL (interquartile
range: 503–864 pg/mL; 5th and 95th centiles: 352 and 1370 pg/mL respectively). The reference
ranges of presepsin we determined weremuch higher than those seen in healthy adults. No cor-
relation between presepsin levels and postnatal age was observed, as well as no significant dif-
ference was demonstrated in preterm neonates at different gestational ages. None of the
variables analyzed affected presepsin levels at a clinical significant extent.
Conclusion
For the first time, this study provides reference ranges of presepsin in term and preterm neo-
nates. Having reliable reference values is crucial for obtaining an adequate diagnostic
PLOS ONE | DOI:10.1371/journal.pone.0146020 December 31, 2015 1 / 11
OPEN ACCESS
Citation: Pugni L, Pietrasanta C, Milani S, Vener C,
Ronchi A, Falbo M, et al. (2015) Presepsin (Soluble
CD14 Subtype): Reference Ranges of a New Sepsis
Marker in Term and Preterm Neonates. PLoS ONE
10(12): e0146020. doi:10.1371/journal.pone.0146020
Editor: Umberto Simeoni, Centre Hospitalier
Universitaire Vaudois, FRANCE
Received: August 29, 2015
Accepted: December 12, 2015
Published: December 31, 2015
Copyright: © 2015 Pugni et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
accuracy. Based on our results, most variables commonly affecting C-reactive protein and
procalcitonin values do not affect presepsin levels, which suggests that presepsin could be
an effective sepsis marker. Further investigations in large groups of neonates with sepsis
are needed to determine the diagnostic and prognostic value of this biomarker.
Introduction
Sepsis is still a major cause of morbidity and mortality in neonates, especially in preterm
infants [1]. Mortality rate can reach 60–70% in very low birth weight infants (birth
weight< 1500 g) [2]. Beyond being a life-threatening condition, sepsis can cause sequelae in
survivors and significantly impair neurodevelopmental outcome [3,4]. Because the disease can
progress rapidly to septic shock and multiple organ dysfunction syndrome, early diagnosis is
crucial to improve survival. Unfortunately, the diagnosis of sepsis may be difficult in the neo-
nate. The earliest signs of the disease are often subtle and non specific, and can be easily con-
fused with signs of non-infectious diseases [1].
Blood culture is the gold standard for the diagnosis of sepsis, but at least 48–72 hours are
needed for the results and the number of false negative results is not negligible, particularly in
early-onset sepsis, for which the blood culture sensitivity is reported to be less than 10% [5]. In
the last decades, a great deal of efforts has been focused on biochemical markers. To date, C-
reactive protein (CRP) and procalcitonin (PCT) are the most widely used markers for sepsis
management in neonatal intensive care unit (NICU). CRP lacks the specificity to consistently
discriminate between infections and non-infectious inflammatory conditions; furthermore, it
rises late [6–10]. PCT has the advantage of increasing faster, and seems to be more specific for
bacterial infections; however, its values depend on gestational age (GA) and postnatal age, par-
ticularly in the first days of life [8–11]. Although the reliability of these and other biomarkers
raises when used together, the search for the optimal sepsis biomarker is far from being
concluded.
In 2005, Yaegashi et al. [12] identified a new biomarker, named soluble CD14 subtype
(sCD14-ST) or presepsin. Cluster of differentiation 14 (CD14) is a glycoprotein expressed on
the membrane surface of various cells, such as monocytes, macrophages and granulocytes, and
serves as a high-affinity receptor for complexes of lipopolysaccharides (LPSs) and LPS-binding
proteins (LBPs), activating the toll-like receptor 4 (TLR4)-specific proinflammatory signaling
cascade against infectious agents. After TLR4 activation, the complex LPS-LBP-CD14 is inter-
nalized into a phagolysosome. Soluble forms of CD14 are produced and released into circula-
tion either by secretion following phagocytosis or through proteolytic cleavage on activated
monocytes. Presepsin is a 13-kDa truncated form consisting of 64 amino acid residues [12–14].
In recent years, several authors evaluated the role of presepsin as a biomarker in adults.
Based on the results of these studies, presepsin appears to offer some advantages over the most
well known and widely used markers such as CRP and PCT, including an earlier increase in
blood levels, higher sensitivity and specificity, and a prognostic value [12,15–23]. Furthermore,
the cost of presepsin measurement is comparable to that of procalcitonin. Nevertheless, very
few studies were conducted in pediatric population [24–28], and data on presepsin in large
groups of term and preterm neonates have never been reported, neither for healthy babies nor
for those with sepsis.
Therefore, we decided to perform a study to determine reference ranges of presepsin in
healthy term neonates and in preterm neonates without clinical signs or symptoms of
infection.
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Materials and Methods
Study population
This was an observational single-center study, conducted at the Neonatal Unit of Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Italy, from February 2014 to
August 2014. The study protocol was approved by the Ethics Committee of the Hospital. Writ-
ten informed consent was obtained from parents for the inclusion in the study, and all proce-
dures were in accordance with the Helsinki Declaration of 1975, as revised in 2008.
Healthy term neonates admitted to the nursery and preterm neonates without clinical signs
or symptoms of local or systemic infection admitted to the NICU were consecutively enrolled.
Exclusion criteria were the presence of major congenital malformations and lack of parental
consent.
Term neonates were defined as those born at a GA greater than or equal to 37 and less than
42 weeks; preterm neonates were defined as those born at a GA less than 37 weeks. GA was
established on the basis of best obstetric estimates, including last menstrual period and first or
second trimester ultrasonography. Term neonates were defined as healthy when they appeared
in good health conditions, with a normal physical examination and no need for medical man-
agement. Preterm neonates with a suspected sepsis were identified, according to Centers for
Disease Control and Prevention (CDC) criteria [29], by the presence of one or more of the fol-
lowing clinical signs or symptoms with no other recognized cause and requiring antibiotic
therapy on physician judgment: fever, hypothermia, grey/pale skin colour, hypotonia, hypor-
eactivity, apnea, polypnea, dyspnea, bradycardia, tachycardia, and hypotension. CDC criteria
[29] were also used to identify infants with local infection. Small for gestational age (SGA) neo-
nates were defined as those with a birth weight less than the 10th centile for age, according to
Bertino’s anthropometric charts [30].
Study design
To determine presepsin levels, 100 μL of whole blood were obtained from term neonates via
heel puncture on day 3–4 of life, at the time of Guthrie screening. The same amount of blood
was obtained from preterm neonates via heel puncture or venipuncture between the 3rd and
the 7th day of life, at the time of Guthrie screening or in conjunction with a blood sampling for
clinical need. Blood was collected in sterile, endotoxin-free tube containing ethylenediamine-
tetraacetic acid (EDTA). All blood samples were stored at room temperature and processed
within 4 hours after collection by physicians appropriately trained using a point-of-care assay
system located in the NICU.
All neonates enrolled in the study were followed-up for one week after the blood sampling,
and those presenting signs or symptoms of local or systemic infection were excluded from the
analysis.
The time of blood sampling was decided after a preliminary study performed on a small
group of 18 neonates with GA between 28 and 40 weeks of gestation assessed for presepsin 1, 3,
10, 21 days after birth: it emerged that neither postnatal age (p = 0.311), nor GA (p = 0.130),
nor interaction age×GA (p = 0.129) appear to exert important effects on presepsin levels.
Data collection
The following variables were considered in this study: mother’s information [fever during
labor, maternal CRP at delivery, vaginal swab, premature (at least 1 hour before the onset of
contractions)–rupture of the membranes (PROM), histological chorioamnionitis in preterm
delivery, pre-eclampsia in preterm delivery], stained amniotic fluid, mode of delivery, birth
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place, gender, ethnicity, number of fetuses, GA, birth weight, weight for GA, Apgar score at 1
and 5 minutes, weight loss at the time of blood sampling, day at maximum weight loss, age at
blood sampling, clinical course during the first 2 weeks of life. For preterm neonates, additional
variables were considered: prenatal steroid exposure, need for resuscitation at birth, including
oxygen and endotracheal intubation in delivery room, urinary output at the time of blood sam-
pling, invasive and non-invasive ventilation, central venous catheterization, parenteral nutri-
tion and antibiotic prophylaxis also at the time of sampling, surfactant administration and
pharmacological treatment of patent ductus arteriosus (PDA) prior to sampling, CRP if per-
formed and any surgery prior to sampling. The clinical risk index for babies (CRIB)-II score
was also calculated for infants 32 weeks’ gestation.
Presepsin measurement
Presepsin concentrations in whole blood were measured using a compact fully automated
immunoassay analyzer, PATHFASTTM System (LSI Medience Corporation, Japan / Mitsubishi
Chemical Europe), based on a non-competitive chemiluminescence enzyme immunoassay
[31]. The assay time is 15 minutes using a sample volume of 100 μL. Results are automatically
corrected by entering the patient’s hematocrit value. For healthy term neonates, a value of 50%
was used based on cord blood hematocrit determined for each newborn that ranged from 40 to
60%, mean value 50% as reported by Jopling et al. [32], considering that presepsin measure-
ment is altered only when the difference between the effective value and the one entered is
greater than 10%. For preterm neonates, hematocrit value was previously measured for routine
test and entered for each of them.
Statistical analysis
Presepin values in term and preterm neonates were modelled as a function of the variables
listed above. To detect which among the above variables affects the presepsin values to a larger
extent, separately for term and preterm neonates, the stepwise approach was adopted, having
fixed a 0.30 significance level to entry a variable into the model and a 0.05 significance level to
mantain a variable in the model. The presepsin values observed in the group of 18 neonates fol-
lowed up to 21 days of postnatal life in the preliminary study were fitted with a repeated mea-
sures linear model: the effects of GA, age (linear component) and interaction “age (linear
component) × GA” were estimated.
Results
Of the 684 neonates enrolled in the study, 484 (70.8%) were born at term and 200 (29.2%) were
preterm (24–36 weeks’ gestation). Five preterm infants were excluded from the analysis due to
signs of infection in the week after the blood sampling.
Mean age at blood sampling was 3.6 days (SD 0.6) in term neonates and 3.9 days (SD 0.8)
in preterm neonates. Mean presepsin value was 649 pg/mL (SD 257) in term neonates, and
720 pg/mL (SD 329) in preterm neonates.
In term infants, full records for all the variables under study were available. Among these
variables possibly affecting presepsin levels, the following were excluded from further analysis:
birth place (only 3 neonates were outborn), Apgar score at 5 min (all neonates had score above
7), and age at blood sampling (almost all neonates underwent blood sampling on the 3rd or 4th
day of life). As shown in Table 1, presepsin levels of term neonates were little affected by the
variables under study when singly considered. The stepwise selection analysis confirmed that
only Apgar at 1 min was significantly associated with presepsin levels (p = 0.032) although to a
negligible extent (R2 = 0.95%).
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In preterm infants, full records for all the variables under study were available, except for
vaginal swab (168 missing cases due to preterm delivery). Among these variables, the following
were excluded from further analysis: maternal health status, i.e. fever during labor and/or ele-
vated maternal CRP at delivery (only 1 pathological case), vaginal swab (because of missing
data), histological chorioamnionitis (only 8 positive cases), pre-eclampsia (only 7 cases), amni-
otic fluid (only 7 cases of stained fluid), birth place (only 16 outborn), urinary output at the
time of blood sampling (only 1 case of diuresis< 1 ml/kg/hour), invasive ventilation at the
time of blood sampling (only 6 cases), pharmacological treatment of PDA (only 3 cases treated
prior to sampling), surgery (only 4 cases of surgery prior to sampling). As shown in Table 2,
presepsin levels of preterm neonates were little affected by almost all the variables under study
when singly considered. The stepwise selection analysis confirmed that presepsin levels were
significantly higher in SGA neonates (p = 0.002, R2 = 5.1%).
Table 3 reports the distribution of prepsepsin levels in term neonates (with and without
exclusion of cases with Apgar score< 8) and preterm neonates (with and without exclusion of
SGA subjects). As expected on the basis of results previously reported (i.e. the very low values
of R2), the exclusion of the term neonates with Apgar score< 8 does not affect the estimates of
the centiles, whereas the exclusion of SGA preterm neonates decreases the 95th centile by 8%
only.
Discussion
Sepsis is a life-threatening condition and continues to be a major challenge for physicians,
especially in intensive care units. Biomarkers play a pivotal role in early diagnosis, risk stratifi-
cation, therapy monitoring and prognosis. In recent years, presepsin, a circulating molecule
fragment derived from CD14, has been shown to be beneficial as sepsis marker in adults
[12,15–23,33–36]. Nevertheless, very few data are available in neonates. Given that reliable ref-
erence values are crucial for obtaining an adequate diagnostic accuracy, we determined for the
first time reference ranges of presepsin in a large group of neonates.
Table 1. Presepsin levels (pg/mL) in term neonates classified by the variables under study, singly considered (means ± standard errors).
variable na meana ± SEa nb meanb ± SEb p
healthya vs pathologicalb maternal status
1 471 651 ± 11.9 13 606 ± 71.4 0.535
negativea vs positiveb vaginal swab 454 649 ± 12.1 30 655 ± 47.0 0.907
normala vs stainedb amniotic ﬂuid 447 655 ± 12.2 37 585 ± 42.2 0.116
spontaneousa vs caesareanb section 272 639 ± 15.6 212 663 ± 17.7 0.318
femalea vs maleb 240 648 ± 16.6 244 651 ± 16.5 0.918
caucasiana vs otherb ethnic groups 407 654 ± 12.8 77 625 ± 29.3 0.357
singletona vs twinb 467 653 ± 11.9 17 538 ± 62.2 0.068
gestational age 37-38a vs 39-41b weeks
2 214 647 ± 17.6 270 651 ± 15.7 0.855
birth weight < 2500a vs  2500b g 25 686 ± 51.5 459 647 ± 12.0 0.464
AGAa vs SGAb 429 651 ± 12.4 55 637 ± 34.7 0.712
Apgar at 1 min  8a vs < 8b 462 645 ± 11.9 21 767 ± 55.9 0.032
weight loss at blood sampling  10%a vs > 10%b 412 652 ± 12.7 72 635 ± 30.3 0.606
day at maximum weight loss  4a vs > 4b 417 646 ± 12.6 67 673 ± 31.4 0.427
AGA: appropriate for gestational age; SGA: small for gestational age
1) fever during labor and/or elevated maternal C-reactive protein at delivery
2) completed weeks of gestation
doi:10.1371/journal.pone.0146020.t001
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The preliminary study we conducted on a small group of neonates with different GA, who
underwent repeated measurements in the first three weeks of life, made us confident enough
that postnatal age does not affect presepsin levels, contrary to what occurs for CRP and PCT.
That was in agreement with previous findings [26,27]. Therefore, we decided to withdraw
blood sampling in the first week of life, at the same time of Guthrie screening.
Table 2. Presepsin levels (pg/mL) in preterm neonates classified by the variables under study, singly considered (means ± standard errors).
variable na meana ± SEa nb meanb ± SEb p
prenatal steroids noa vs yesb 89 750 ± 34.8 106 694 ± 31.9 0.237
rupture of membranes  1a vs < 1b hour 47 711 ± 48.1 148 723 ± 27.1 0.826
spontaneousa vs caesareanb section 42 699 ± 50.9 153 726 ± 26.7 0.642
femalea vs maleb 100 693 ± 32.9 95 748 ± 33.7 0.248
caucasiana vs otherb ethnic groups 164 711 ± 25.7 31 766 ± 59.1 0.394
singletona vs twinb 111 723 ± 31.3 84 716 ± 36.0 0.881
gestational age  32a vs < 32b weeks1 158 713 ± 26.2 37 747 ± 54.2 0.575
birth weight  1500a vs < 1500b g 159 714 ± 26.1 36 746 ± 54.9 0.594
AGAa vs SGAb 161 686 ± 25.3 34 881 ± 55.1 0.002
Apgar at 1 min  8a vs < 8b 131 733 ± 28.7 62 697 ± 41.8 0.482
Apgar at 5 min  8a vs < 8b 176 715 ± 24.8 17 790 ± 79.7 0.372
resuscitation in delivery room noa vs yesb
2 134 732 ± 28.5 61 693 ± 42.2 0.443
oxygen in delivery room noa vs yesb 156 729 ± 26.4 39 683 ± 52.7 0.440
endotracheal intubation in delivery room noa vs yesb 180 710 ± 24.5 15 834 ± 84.8 0.164
CRIB-II score  4a vs > 4b3 28 692 ± 62.5 23 772 ± 69.0 0.394
ventilation at blood sampling noa vs yesb
4 149 701 ± 26.9 46 781 ± 48.4 0.150
central venous catheter at blood sampling noa vs yesb 143 702 ± 27.5 52 769 ± 45.6 0.205
parenteral nutrition at blood sampling noa vs yesb 59 744 ± 42.9 136 709 ± 28.3 0.506
antibiotic prophylaxis at blood sampling noa vs yesb 130 722 ± 28.9 65 716 ± 40.9 0.911
surfactant in the days before sampling noa vs yesb 164 713 ± 25.7 31 754 ± 59.2 0.534
weight loss at blood sampling  10%a vs > 10%b 152 721 ± 26.8 43 717 ± 50.3 0.944
day at maximum weight loss  4a vs > 4b 96 720 ± 33.7 99 720 ± 33.2 0.995
day at blood sampling  4a vs > 4b 139 691 ± 27.7 56 791 ± 43.7 0.055
AGA: appropriate for gestational age; SGA: small for gestational age
1) completed weeks of gestation
2) at least ventilation with mask
3) CRIB (clinical risk index for babies)-II score: calculated in infants  32 weeks’ gestation
4) all ventilated neonates were on non-invasive ventilation
doi:10.1371/journal.pone.0146020.t002
Table 3. Centiles of the distribution of presepsin levels (pg/mL) in term and preterm neonates.
Group n 5th 10th 25th 50th 75th 90th 95th
term 484 315 371 466 604 791 1000 1178
term1 462 311 366 462 600 773 986 1178
preterm 195 352 390 503 620 864 1160 1370
preterm2 161 352 389 499 595 824 1049 1256
1) after exclusion of 21 neonates with Apgar score at 1 min < 8
2) after exclusion of 34 SGA neonates
doi:10.1371/journal.pone.0146020.t003
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Term and preterm neonates were evaluated separately, considering that preterm infants
are often suffering from diseases related to prematurity and consequently not classifiable as
“healthy”. In term infants, presepsin median value on day 3 or 4 of life was 603.5 pg/mL (inter-
quartile range: 466.5–791 pg/mL; 5th and 95th centiles: 315 and 1178 pg/mL respectively). In
preterm infants without clinical signs or symptoms of local or systemic infection, presepsin
median value between the 3rd and the 7th day of life was slightly higher, equal to 620 pg/mL
(interquartile range: 503–864 pg/mL; 5th and 95th centiles: 352 and 1370 pg/mL respectively).
In 2012, Mussap et al. [24] reported a presepsin median value of 578 pg/mL (interquartile
range: 453–796 pg/mL) in 26 non-septic preterm neonates with a GA between 26 and 36 weeks
and a postnatal age between 25 and 160 hours. In the same year, Casani et al. [25] found a pre-
sepsin mean value of 953 pg/mL (interquartile range: 661–1114 pg/mL) in cord blood from
64 term or near-term (34–36 weeks’ gestation) neonates, and a mean value of 741 pg/mL
(interquartile range: 490–937 pg/mL) in blood samples collected on the 3rd day of life in 24 of
the 64 infants enrolled. In a case-control study by Poggi et al. [26], conducted to evaluate the
diagnostic accuracy of presepsin for the diagnosis of late-onset sepsis in preterm infants with
GA 32 weeks and postnatal age between 4 and 60 days, presepsin median value at enrollment
was 562 pg/mL (interquartile range: 337–726 pg/mL) in the 21 control subjects. In another
recent case-control study by Topcuoglu et al. [27], a presepsin median value of 530 pg/mL
(interquartile range: 363–580 pg/mL) was reported in a group of 40 control subjects with
GA 32 weeks and postnatal age between 4 and 30 days. Very recently, Mussap et al. [28]
reported a presepsin median value of 453 pg/mL (interquartile range: 309–526 pg/mL) in a
group of 25 control subjects with GA less than 37 weeks.
The median value of presepsin we found in preterm neonates was slightly higher than that
reported in the above studies, as well as the value corresponding to the 75th centile. On the con-
trary, the values we found in term infants were lower compared to those reported by Casani
[25] in his series of term/near-term neonates. None of the papers cited reported the 5th and
95th centiles.
In planning this study, we set ourselves two main objectives: 1) understanding whether pre-
sepsin levels change at different gestational ages; 2) evaluating the effect of antenatal and peri-
natal variables on presepsin values, considering that biomarkers such as CRP and PCT may be
elevated in the first days of life or in non-infectious conditions [6–8,11].
First, we found presepsin levels slightly higher in preterm neonates compared to those born
at term. In term neonates, no significant difference was found between early-term neonates
(37–38 weeks’ gestation) and neonates with a GA more than 38 weeks, as well as in preterm
neonates no significant difference was demonstrated between neonates with a GA less than
32 weeks (extreme-severe prematurity) and those with a GA of 32 weeks or more (moderate
prematurity-near-term). For term neonates, no data are available in the literature to compare
with our findings, while for premature babies our results are in agreement with those reported
by Mussap et al. [24] that found no difference in the two subgroups of premature babies stud-
ied, with a GA of 30 weeks or less and a GA more than 30 weeks. Therefore, we suggest to
adopt an unique reference range for term neonates and an unique reference range for those
born preterm, regardless of GA.
Second, we tried to detect antenatal or perinatal variables, particularly infectious and pro-
inflammatory risk factors, that could affect presepsin levels in non-infectious neonates. Identi-
fying variables that influence the interpretation of a biomarker in symptomatic neonates or in
neonates at risk for infection may represent an important aid in the differential diagnosis of
sepsis. It is well known that an increased level of CRP, the most widely used marker of sepsis in
NICU, is not necessarily diagnostic for sepsis, as elevations may also occur due to the physio-
logic rise after birth or non-infectious conditions, such as maternal fever during labor, PROM,
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vaginal delivery, fetal distress, perinatal asphyxia, meconium aspiration, respiratory distress
syndrome, and surfactant administration [6–8]. In addition, Chiesa et al. [8] observed that neo-
nates prenatally exposed to steroids had increased CRP concentrations. None of the variables
listed above significantly affected presepsin levels in our study.
Among the variables analyzed in our study, only Apgar score at 1 min ( 8 vs< 8) and
weight for GA (AGA vs SGA) appeared to be slightly, but significantly associated with presep-
sin levels. Nonetheless, the exclusion of term neonates with Apgar score at 1 min< 8 and of
SGA preterm neonates resulted in a small decrease of the centiles above the median, so that
these two variables can be safely ignored in the definition of the reference limits for presepsin
in neonates.
In preterm neonates 32 weeks’ gestation, CRIB-II score was calculated within 1 hour after
admission to the NICU [37]. A CRIB-II score> 4 is associated with a higher risk of mortality
[38]. No difference in presepsin values was observed between CRIB-II score> 4 and 4.
Finally, as increased presepsin concentrations were observed in adult patients with kidney dis-
function, we also evaluated as factors possibly affecting presepsin values an excessive weight
loss and an urinary output< 1 mL/kg/hour. No difference in presepsin values was observed
between weight loss at blood sampling 10 and> 10%. Only one preterm neonate enrolled in
the study had oliguria. Therefore, we believe that this aspect should be investigated in a popula-
tion of selected infants [39–41].
Given that the variables analyzed in our study did not affect presepsin levels at a clinical sig-
nificant extent, we are confident that presepsin might discriminate between infections and
non-infectious inflammatory conditions better than the currently most used biomarkers.
The reference ranges of presepsin we determined, as well as those reported by other authors
in infants without signs of infection, were substantially higher than those seen in healthy adults
[12,15,18,20,21,40]. Very recently, Giavarina et al. [42] reported that the reference limits for
presepsin in 200 adult subjects free from inflammatory diseases were 55–184 pg/mL, corre-
sponding to the 2.5th and 97.5th centiles. The activation of the innate immune system occurring
after birth as a result of the transition from the normally sterile intra-uterine environment to a
world that is rich in foreign antigens could partly explain the higher levels of presepin seen in
healthy babies compared to healthy adults. Following birth, the neonatal skin and gut are rap-
idly colonized with microbial flora and this is a continuous stimulus to the innate immune sys-
tem [43–45]. Moreover, it is known that TLR sensor function is well developed in newborns
and an excessive reactivity of the TLR innate response has also been described. In agreement
with other authors, Levy et al. [45] demonstrated that preterm and full-term neonates express
significantly greater levels of TLR4 on peripheral blood monocytes both at baseline and after
LPS stimulation, compared with adults. In the same study, they also observed significantly
greater CD14 expression at baseline and after LPS stimulation in full-term neonates compared
with adults.
Although presepsin values found in healthy neonates are higher than in adults and show a
greater variability, we expect that presepsin could be a reliable sepsis marker in neonates, as in
adults, considering that concentration levels seem to be independent of GA, postnatal age and
most variables commonly affecting CRP and PCT values. To date, only three studies [26–28]
were conducted on small groups of neonates to evaluate the diagnostic accuracy of presepsin in
the neonatal period. According to these studies, presepsin seems to be an accurate test for the
diagnosis of late-onset sepsis in preterm infants.
The strength of our study includes the high number of term and preterm neonates enrolled,
as well as the high number of variables studied. Strict inclusion criteria allowed us to determine
reference ranges of presepsin in neonates without infectious diseases. Furthermore, presepsin
measurement was always performed in the NICU by few physicians appropriately trained.
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The main limitation of our study was that we have not evaluated a large group of extremely
preterm infants.
In the present study, we have determined for the first time reference ranges of presepsin in a
large group of term and preterm neonates. Presepsin values were found to be slightly higher in
preterm neonates compared to those born at term, and higher than in healthy adult population.
Based on our results, most variables commonly affecting CRP and PCT values do not affect
presepsin levels, which suggests that presepsin could be an effective sepsis marker. Further
investigations in large groups of neonates with sepsis are needed to determine the diagnostic
and prognostic value of this biomarker.
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